Area of research
Rheumatology · Hematology
Research interest
Research focused on Adverse effect and Hazard ratio, with related work in Progressive supranuclear palsy, Perspective (graphical), Bispecific antibody. Notable publications include 'Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial', 'A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma', and 'Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory...'.
The role of responsive MRI probes in the past and the future of molecular imaging
A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
Efficacy and safety of inactivated <scp>SARS‐CoV</scp>‐2 vaccination in <scp>COVID</scp>‐19‐associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real‐world retrospective observational study
Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus
Creatinine clearance rate predicts prognosis of patients with systemic lupus erythematosus: a large retrospective cohort study